The present invention belongs to the technical field of medicines, and relates to a crystal form of a compound used as a mineralocorticoid receptor antagonist and a preparation method therefor, and in particular, to a method for preparing a compound 2-chloro-4-[(3S,3aR)-3-cyclopentyl-7-(4-hydroxypiperidin-1-carbonyl)-3,3a,4,5-tetrahydro-2H-pyrazolo[3,4-f]quinolin-2-yl]benzonitrile of formula (1); a crystal form thereof, a preparation method for the crystal form, and the use of the crystal form in the preparation of drugs for the treatment and/or prevention of renal injury or cardiovascular diseases. ##STR00001##

A composition, consisting essentially of copper, a fluoroalkyl group, and a ligand comprising at least one group-V donor. The molar ratio of copper to the fluoroalkyl group is approximately 1.

A composition, consisting essentially of copper, a fluoroalkyl group, and a ligand comprising at least one group-V donor. The molar ratio of copper to the fluoroalkyl group is approximately 1.

An organic compound that emits red light having a long wavelength and that is represented by formula [1] below. In the formula [1], R.sub.1 to R.sub.24 are each independently selected from a hydrogen atom or a substituent. ##STR00001##

Method of improving the performance and safety of a Li-ion battery. The method includes using a nitrile-based small organic compound of general formula I, V or IX outlined in the application in association with the electrolyte of the battery. An electrolyte including a nitrile-based small organic compound. A battery including the electrolyte.

Method of improving the performance and safety of a Li-ion battery. The method includes using a nitrile-based small organic compound of general formula I, V or IX outlined in the application in association with the electrolyte of the battery. An electrolyte including a nitrile-based small organic compound. A battery including the electrolyte.

The invention provides novel compounds having the general formula (I) ##STR00001##
wherein R.sub.A, R.sub.B, R.sub.C, R.sub.C1 and W are as defined herein, compositions including the compounds and methods of using the compounds.

A method for forming a carbon-carbon bond, wherein a reaction is performed by filling a platinum group metal-supported catalyst into a filling container, and passing a raw material liquid through the platinum group metal-supported catalyst in a continuous circulation manner, and wherein the platinum group metal-supported catalyst is a platinum group metal-supported catalyst in which nanoparticles of a platinum group metal with an average particle diameter of 1 to 100 nm are supported on a non-particulate organic porous ion exchanger formed of a continuous framework phase and a continuous pore phase.

A method for forming a carbon-carbon bond, wherein a reaction is performed by filling a platinum group metal-supported catalyst into a filling container, and passing a raw material liquid through the platinum group metal-supported catalyst in a continuous circulation manner, and wherein the platinum group metal-supported catalyst is a platinum group metal-supported catalyst in which nanoparticles of a platinum group metal with an average particle diameter of 1 to 100 nm are supported on a non-particulate organic porous ion exchanger formed of a continuous framework phase and a continuous pore phase.

A compound: ##STR00001##
wherein X.sup.1 represents an alkenylene group, a —NH—CO— group, a —CO—NH— group, Y.sup.1 represents an aryl group selected from pyridyl, pyrazinyl or pyrimidinyl, X.sup.2 represents —O—, —CO—NH—, —NH—CO—NH—, —OCH.sub.2—, —NH—CO—, a divalent 5-membered heteroaromatic ring comprising 1 to 4 heteroatoms or —SO.sub.2—NH—, and Y.sup.2 represents a hydrogen atom, a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C.sub.1-C.sub.4)alkyl group, a piperazinyl group, optionally substituted by a (C.sub.1-C.sub.4)alkyl group, or —CR.sup.1R.sup.2R.sup.3 or alternatively X.sup.2—Y.sup.2 represents —CONR.sub.cR.sub.d, wherein R.sub.c and R.sub.d form, together with the nitrogen atom a heterocyclic ring, optionally substituted by one or two (C.sub.1-C.sub.4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification.